Document Detail

The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
MedLine Citation:
PMID:  21893558     Owner:  NLM     Status:  MEDLINE    
Biomarkers are being increasingly used in the study of cardiovascular disease because they provide readily quantifiable surrogate endpoints and allow accurate assessment of the effects of therapy on particular pathological processes. However, in order to be useful, biomarkers must be relevant, predictable, accurate, and reproducible. There is compelling evidence from large-scale clinical trials that inhibitors of the renin-angiotensin system [angiotensin-converting enzyme inhibitors and angiotensin type II receptor blockers (ARBs)] and calcium channel blockers (CCBs) may have beneficial effects beyond blood pressure control in the treatment of hypertension. Biomarkers are expected to provide further insight into these beneficial effects and allow for quantitative assessment. This review summarizes the published clinical evidence on the effects of various antihypertensive drugs, particularly ARBs (e.g. losartan and olmesartan medoxomil) and CCBs (e.g. amlodipine), alone and in combination with other agents (e.g. hydrochlorothiazide), on central aortic pressure and the biomarkers high-sensitivity C-reactive protein (hsCRP), adiponectin, cystatin C, homeostasis model assessment of insulin resistance (HOMA-IR), procollagen, tumor necrosis factor-α, and interleukin-6. Of these biomarkers, the benefits of antihypertensive therapy on hsCRP, adiponectin, and HOMA-IR reflect a potential for quantifiable long-term vascular benefits.
Bobby V Khan
Related Documents :
21942118 - Impact of yoga on haemodynamic function in healthy medical students.
21728908 - Mechanical ventilation during anaesthesia: challenges and opportunities for investigati...
226658 - Profile of mood states: the factors and their physiological correlates.
11965468 - Optimal mesh size for endoscopic inguinal hernia repair: a study in a porcine model.
21713728 - Bonfils fiberscope: intubating conditions and hemodynamic changes without neuromuscular...
8788218 - Hypertension risk factors and cardiovascular reactivity to mental stress in young men.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2011-09-05
Journal Detail:
Title:  Therapeutic advances in cardiovascular disease     Volume:  5     ISSN:  1753-9455     ISO Abbreviation:  Ther Adv Cardiovasc Dis     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2011-09-22     Completed Date:  2012-01-19     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  101316343     Medline TA:  Ther Adv Cardiovasc Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  241-73     Citation Subset:  IM    
Copyright Information:
© The Author(s), 2011.
Atlanta Vascular Research Foundation, Saint Joseph's Translational Research Institute, 3562 Habersham at Northlake, Atlanta, GA 30084, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amlodipine / administration & dosage,  pharmacology,  therapeutic use
Antihypertensive Agents / administration & dosage,  pharmacology,  therapeutic use*
Biological Markers / metabolism
Blood Pressure / drug effects*
Drug Therapy, Combination
Hypertension / drug therapy*,  physiopathology
Imidazoles / administration & dosage,  pharmacology,  therapeutic use
Losartan / administration & dosage,  pharmacology,  therapeutic use
Reproducibility of Results
Tetrazoles / administration & dosage,  pharmacology,  therapeutic use
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biological Markers; 0/Imidazoles; 0/Tetrazoles; 114798-26-4/Losartan; 6M97XTV3HD/olmesartan medoxomil; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigem...
Next Document:  The facts behind niacin.